Search for content, post, videos

Carbiotix signs collaboration agreement

Carbiotix has signed a collaboration agreement with the Department of Medicine at the University of Verona, Italy, to carry out a research study during H1 2020 in the area of neuroinflammation using Carbiotix Microbiome Modulator Therapeutics (MMT).

The collaboration agreement will seek to find new MMT applications and further validate Carbiotix MMT platform. The study will focus on the impact of Short Chain Fatty Acids (SCFAs) or metabolites produced from Carbiotix Microbiome Modulator Therapeutics (MMT) on modulating neutrophil functionalities, and the contribution of these cells to neuroinflammation.

Carbiotix first academic partnership

“This collaboration agreement represents Carbiotix first academic partnership to explore the potential of the company´s MMT platform across different indication areas. We were approached by Dr. Elena Zenaro from the Department of Medicine who validated in her research a link between elevated levels of specific metabolites and a reduced risk of developing neuroinflammation. Dr. Elena Zenaro saw our MMT platform as an interesting technology given our focus on elevating key metabolites in individuals. The collaboration agreement is our first academic collaboration and our ambition is to continue to build similar partnerships across other indication areas as a means to cost-effectively investigate new MMT applications, validate the breadth of our MMT platform, and access expert knowledge in each respective indication area,” says Kristofer Cook, CEO for Carbiotix.